StreetInsider.com News Articles

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Fri, 07 Aug 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260807/26892369.html

Form 144 GLAUKOS Corp Filed by: Thurman Alex R.

Fri, 07 Aug 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260807/26892369.html

Form 4 GLAUKOS Corp For: Jul 31 Filed by: WEN LEANA

Mon, 03 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260803/26858788.html

Form 4 GLAUKOS Corp For: Jul 31 Filed by: WEN LEANA

Mon, 03 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260803/26858788.html

Form 8-K GLAUKOS Corp For: Aug 03

Mon, 03 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260803/26853726.html

Form 8-K GLAUKOS Corp For: Aug 03

Mon, 03 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260803/26853726.html

Form 144 GLAUKOS Corp Filed by: WEN LEANA

Fri, 31 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260731/26851033.html

Form 144 GLAUKOS Corp Filed by: WEN LEANA

Fri, 31 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260731/26851033.html

Glaukos Corporation (GKOS) PT Raised to $195 at H.C. Wainwright

Fri, 31 Jul 2026 06:44:42 -0400

(Updated - July 31, 2026 6:44 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Glaukos Corporation (NYSE: GKOS) to $195.00 (from $168.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Glaukos reported its 2Q26 financial results. Total revenue was $185.6M, representing 49.5% YoY growth and beating our projection of $151.5M. Specifically, glaucoma revenue was $155.2M, up 49.9% YoY; and corneal health revenue was $30.4M, up 47.8% YoY. Net loss was $18.4M, or ($0.31) per share, less than our estimated loss of $19.3M. Management noted that the strong growth momentum was driven by two drivers: iDose TR and

Glaukos Corporation (GKOS) PT Raised to $195 at H.C. Wainwright

Fri, 31 Jul 2026 06:44:42 -0400

(Updated - July 31, 2026 6:44 AM EDT)

H.C. Wainwright analyst Yi Chen raised the price target on Glaukos Corporation (NYSE: GKOS) to $195.00 (from $168.00) while maintaining a Buy rating.

Glaukos Corporation (GKOS) PT Raised to $190 at Stifel

Thu, 30 Jul 2026 10:55:24 -0400

Stifel analyst Thomas Stephan raised the price target on Glaukos Corporation (NYSE: GKOS) to $190.00 (from $175.00) while maintaining a Buy rating.

The analyst commented, "Equinix delivered a strong 2Q beat and materially strengthened its LT outlook, underscoring accelerating AI-driven demand, near-record bookings, and improving earnings. Management raised its 2027-2029 financial framework, increasing annual revenue growth targets to 10%-13%, EBITDA margins to 53%+, and AFFO/share growth to 9%-12%, while expanding annual CapEx to $5-7B to support growing AI and enterprise inference deployments. For 2026, Equinix issued its largest guidance increase in company history, raising revenue, EBITDA, and AFFO/share expectations following strong

Glaukos Corporation (GKOS) PT Raised to $190 at Stifel

Thu, 30 Jul 2026 10:55:24 -0400

Stifel analyst Thomas Stephan raised the price target on Glaukos Corporation (NYSE: GKOS) to $190.00 (from $175.00) while maintaining a Buy rating.

Glaukos Corporation (GKOS) PT Raised to $172 at UBS

Thu, 30 Jul 2026 09:35:45 -0400

UBS analyst Patrick Wood raised the price target on Glaukos Corporation (NYSE: GKOS) to $172.00 (from $150.00) while maintaining a Neutral rating.

Glaukos Corporation (GKOS) PT Raised to $178 at Wells Fargo

Thu, 30 Jul 2026 08:35:06 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on Glaukos Corporation (NYSE: GKOS) to $178.00 (from $138.00) while maintaining a Overweight rating.

Glaukos Corporation (GKOS) PT Raised to $185 at Mizuho

Thu, 30 Jul 2026 07:10:39 -0400

Mizuho analyst Anthony Petrone raised the price target on Glaukos Corporation (NYSE: GKOS) to $185.00 (from $160.00) while maintaining a Outperform rating.

Glaukos Corporation (GKOS) PT Raised to $195 at Piper Sandler

Thu, 30 Jul 2026 07:09:45 -0400

Piper Sandler analyst Adam C. Maeder raised the price target on Glaukos Corporation (NYSE: GKOS) to $195.00 (from $165.00) while maintaining a Overweight rating.

Glaukos Corporation (GKOS) PT Raised to $201 at Needham

Thu, 30 Jul 2026 06:10:44 -0400

(Updated - July 30, 2026 6:10 AM EDT)

Needham analyst David Saxon raised the price target on Glaukos Corporation (NYSE: GKOS) to $201.00 (from $150.00) while maintaining a Buy rating.

The analyst commented: "GKOS' 2Q26 revenue beat consensus driven by iDose and early, but meaningful, Epioxa contribution, and management raised its 2026 revenue guidance 10% at the mid-point. iDose saw significant sequential growth while Epioxa contributed $11M in its first full commercial quarter. We believe there are multiple sources of meaningful potential upside to estimates leading us to reiterate our Buy rating and raise our price target to $201 on our higher

Glaukos Corporation (GKOS) PT Raised to $201 at Needham

Thu, 30 Jul 2026 06:10:44 -0400

(Updated - July 30, 2026 6:10 AM EDT)

Needham analyst David Saxon raised the price target on Glaukos Corporation (NYSE: GKOS) to $201.00 (from $150.00) while maintaining a Buy rating.

Glaukos Corporation (GKOS) PT Raised to $215 at Truist Securities

Thu, 30 Jul 2026 05:05:01 -0400

Truist Securities analyst Richard Newitter raised the price target on Glaukos Corporation (NYSE: GKOS) to $215.00 (from $180.00) while maintaining a Buy rating.

The analyst comments "Our PT increases to $215 ($180 prior) based on higher estimates. This includes ~$90 valuation for iDose (vs. $105) --which works out to ~18x/13x our lower ‘27E/‘28E iDose forecasts; (b) a ~$16 value for GKOS’ Glaucoma business ex-iDose--which works out to ~2x our '27E EV/Sales (below ophthalmic MedTech peers); and (c) ~$107/shr for Corneal Health (vs. $60)—which works out to 23x/14.5x our increased ‘27E/’28E Corneal Health forecasts reflecting our increased confidence in out-yr upside potential

Glaukos Corporation (GKOS) PT Raised to $215 at Truist Securities

Thu, 30 Jul 2026 05:05:01 -0400

Truist Securities analyst Richard Newitter raised the price target on Glaukos Corporation (NYSE: GKOS) to $215.00 (from $180.00) while maintaining a Buy rating.

Form 10-Q GLAUKOS Corp For: Jun 30

Wed, 29 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260729/26836398.html

Form 10-Q GLAUKOS Corp For: Jun 30

Wed, 29 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260729/26836398.html

Glaukos Corporation (GKOS) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY26 Revenue Guidance

Wed, 29 Jul 2026 16:25:37 -0400

Glaukos Corporation (NYSE: GKOS) reported Q2 EPS of ($0.14), $0.07 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $185.6 million versus the consensus estimate of $151.13 million.

GUIDANCE:

Glaukos Corporation sees FY2026 revenue of $680-700 million, versus the consensus of $630 million.

For earnings history and earnings-related data on Glaukos Corporation (GKOS) click here.

Glaukos Corporation (GKOS) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY26 Revenue Guidance

Wed, 29 Jul 2026 16:25:37 -0400

GUIDANCE:

Glaukos Corporation sees FY2026 revenue of $680-700 million, versus the consensus of $630 million.

For earnings history and earnings-related data on Glaukos Corporation (GKOS) click here.

Form 8-K GLAUKOS Corp For: Jul 29

Wed, 29 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260729/26835069.html